Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies.
Cummings BB, Joing MP, Bouchard PR, Milton MN, Moesta PF, Ramanan V, Lane A, Hirman J, Trauger JW, Maratos-Flier E, Voznesensky A, Splawski I, Nimonkar AV, Flaherty MM, Yi BA, Meyers D, Huet F, Sahambi SK, Yates DP, Hom D, Hinder M, Basson CT, O'Donnell C, Siegelman ES, Garrett CE, Lehrer-Graiwer J, Juliano RA, Weiss EJ.
Cummings BB, et al. Among authors: garrett ce.
Lancet. 2025 May 31;405(10493):1923-1934. doi: 10.1016/S0140-6736(25)00825-6. Epub 2025 May 15.
Lancet. 2025.
PMID: 40383129
Clinical Trial.